Baird Capital has invested in Oncology Analytics, a data analytics and technology-enabled services company dedicated to helping health plans, providers, and patients with solutions that are purpose-built for oncology.
The investment will enable Oncology Analytics to expand its oncology-focused capabilities, accelerate real-world data and analytics solutions for health plans, and increase the market share of its technology-enabled utilisation management solution.
Mike Liang, Partner at Baird Capital, said: "The increasing cost of cancer care in the US has created an enormous burden for health plans and patients, which requires new thinking and a radical approach to solve. Oncology Analytics’ strategy, which puts data-science and real-world evidence at the centre of the treatment decision-making process, demonstrates the type of innovative leadership needed in healthcare. Baird Capital looks forward to supporting Oncology Analytics to accelerate its mission."
Rick Dean, CEO of Oncology Analytics, added: "It is incredibly humbling to have such a talented and experienced group of healthcare investors support our efforts to transform the oncology benefits landscape. We are delighted to welcome Michael and Baird Capital to the team, as I know this collaboration will accelerate our ability to bring value and innovation to our health plan customers."
